Ligand ID: RKE


Drugbank ID:
DB01221
(Ketamine)


Indication:
Ketamine is indicated as an anesthetic agent for recommended diagnostic and surgical procedures. If skeletal muscle relaxation is needed, it should be combined with a muscle relaxant. If the surgical procedure involves visceral pain, it should be supplemented with an agent that obtunds visceral pain. Ketamine can be used for induction of anesthesia prior other general anesthetic agents and as a supplement of low potency agents.[L1336, FDA label]

Get human targets for RKE in PDB (known and potential targets)

RESULTS FROM SUB-STRUCTURAL SIMILARITY SEARCHES MAPPED TO LIGAND 'RKE'

Click here for results that match SARS-Cov-2 / COVID-19 structures only
Click here for results that match SARS-related structures only


1) User may click on the DrReposER ID (the second column) to get information on the binding sites and drug molecule.
2) Click View (the second last column) to view matched residues and superposition in the NGL viewer (upper right part).
3) User may also click on the Dock (the last column) to get script for molecular docking in UCSF Chimera through AutoDock Vina.

DrReposER ID / Desc. Hit
PDBID		 Hit
Macromolecule		 Res.
Matches		 View Interface RMSD Seq.
Identity (%)		 HETATM Dock
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		2ajf SPIKE PROTEIN
(SARSr-CoV)		4 / 8
ASP F 392
ASP F 393
VAL F 337
PHE F 483
1.05A18.67
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		2dd8 SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 8
ASP S 392
ASP S 393
VAL S 337
PHE S 483
1.06A19.94
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		2gdt NSP1 (EC 3.4.22.-)
P65 HOMOLOG
LEADER PROTEIN
(SARSr)		4 / 8
ASP A  64
ASP A  64
VAL A  78
LEU A  93
1.01A17.35
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		2ghw SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 8
ASP C 392
ASP C 393
VAL C 337
PHE C 483
1.25A19.94
 CL  C  20 ( 4.9A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		2ozk URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		4 / 8
ASP B 300
VAL B 236
PHE B 221
LEU B 227
1.23A22.38
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		2rhb URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARSr-CoV)		4 / 8
ASP C 300
VAL C 236
PHE C 221
LEU C 227
1.24A22.38
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		3bgf SPIKE PROTEIN S1
(SARSr-CoV)		4 / 8
ASP A 392
ASP A 393
VAL A 337
PHE A 483
1.18A20.07
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		3d0g SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 8
ASP F 392
ASP F 393
VAL F 337
PHE F 483
1.18A18.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		3d0h SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 8
ASP F 392
ASP F 393
VAL F 337
PHE F 483
1.23A18.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		3d0i SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 8
ASP E 392
ASP E 393
VAL E 337
PHE E 483
1.24A19.30
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		3i6k BETA-2-MICROGLOBULIN
(Homo
sapiens)		4 / 8
ASP B  34
VAL B  82
PHE B  30
LEU B  64
1.39A16.88
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		3sci SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 8
ASP F 392
ASP F 393
VAL F 337
PHE F 483
1.20A21.45
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		3scj SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 8
ASP E 392
ASP E 393
VAL E 337
PHE E 483
1.21A18.67
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		3sck SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 8
ASP E 392
ASP E 393
VAL E 337
PHE E 483
1.17A18.99
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		3scl SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 8
ASP F 392
ASP F 393
VAL F 337
PHE F 483
1.32A18.67
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		4rna PAPAIN-LIKE PROTEASE
(Human
betacoronavirus
2c
EMC/2012)		4 / 8
ASP A 302
VAL A 268
LEU A 284
LYS A 291
1.34A19.73
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
ASN A 203
ASP A 289
VAL A 296
LEU A 205
1.52A18.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
ASN A 203
ASP A 289
VAL A 296
LEU A 205
1.53A18.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
ASN A 203
ASP A 289
VAL A 296
LEU A 205
1.54A18.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
ASN A 203
ASP A 289
VAL A 296
LEU A 205
1.52A18.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_E_RKEE401_1
(PROTON-GATED ION
CHANNEL)		5rfc 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
VAL A 296
LEU A 205
ASN A 203
ASP A 289
1.52A18.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		5x5b SPIKE GLYCOPROTEIN
(SARS-COV
BJ01)		4 / 8
ASP B 376
VAL B 369
PHE B 379
LEU B 503
1.26A13.53
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		5xlr SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 8
TYR B 494
ASP B 392
ASP B 393
PHE B 483
1.25A14.04
TYR  B 494 ( 1.3A)
ASP  B 392 ( 0.5A)
ASP  B 393 ( 0.5A)
PHE  B 483 ( 1.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		6acg SPIKE GLYCOPROTEIN
(SARSr-CoV)		4 / 8
ASP B 392
ASP B 393
VAL B 337
PHE B 483
1.14A14.04
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		6crw SPIKE
GLYCOPROTEIN,FIBRITI
N
(SARSr-CoV)		4 / 8
ASP A 392
ASP A 393
VAL A 337
PHE A 483
1.17A14.02
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		6lze VIRAL PROTEASE
(SARS-CoV-2)		4 / 8
ASP A 229
VAL A 233
LEU A 242
LYS A 269
1.77A21.78

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		6lze VIRAL PROTEASE
(SARS-CoV-2)		4 / 8
ASN A 203
ASP A 289
VAL A 296
LEU A 205
1.54A21.78

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_E_RKEE401_1
(PROTON-GATED ION
CHANNEL)		6lze VIRAL PROTEASE
(SARS-CoV-2)		4 / 8
VAL A 233
LEU A 242
LYS A 269
ASP A 229
1.77A21.78

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_E_RKEE401_1
(PROTON-GATED ION
CHANNEL)		6lze VIRAL PROTEASE
(SARS-CoV-2)		4 / 8
VAL A 296
LEU A 205
ASN A 203
ASP A 289
1.54A21.78

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		6lze VIRAL PROTEASE
(SARS-CoV-2)		4 / 8
ASN A 203
ASP A 289
VAL A 296
LEU A 205
1.54A21.78

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		6lze VIRAL PROTEASE
(SARS-CoV-2)		4 / 8
ASN A 203
ASP A 289
VAL A 296
LEU A 205
1.55A21.78

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		6lze VIRAL PROTEASE
(SARS-CoV-2)		4 / 8
ASP A 229
VAL A 233
LEU A 242
LYS A 269
1.76A21.78

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		6lze VIRAL PROTEASE
(SARS-CoV-2)		4 / 8
ASP A 229
VAL A 233
LEU A 242
LYS A 269
1.77A21.78

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		6lze VIRAL PROTEASE
(SARS-CoV-2)		4 / 8
ASN A 203
ASP A 289
VAL A 296
LEU A 205
1.54A21.78

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		6lze VIRAL PROTEASE
(SARS-CoV-2)		4 / 8
ASP A 229
VAL A 233
LEU A 242
LYS A 269
1.77A21.78

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		6m0k VIRAL PROTEASE
(SARS-CoV-2)		4 / 8
ASN A 203
ASP A 289
VAL A 296
LEU A 205
1.56A21.78

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		6m0k VIRAL PROTEASE
(SARS-CoV-2)		4 / 8
ASN A 203
ASP A 289
VAL A 296
LEU A 205
1.55A21.78

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		6m0k VIRAL PROTEASE
(SARS-CoV-2)		4 / 8
ASN A 203
ASP A 289
VAL A 296
LEU A 205
1.55A21.78

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_E_RKEE401_1
(PROTON-GATED ION
CHANNEL)		6m0k VIRAL PROTEASE
(SARS-CoV-2)		4 / 8
VAL A 296
LEU A 205
ASN A 203
ASP A 289
1.55A21.78

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		6m0k VIRAL PROTEASE
(SARS-CoV-2)		4 / 8
ASP A 229
VAL A 233
LEU A 242
LYS A 269
1.79A21.78

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		6m0k VIRAL PROTEASE
(SARS-CoV-2)		4 / 8
ASN A 203
ASP A 289
VAL A 296
LEU A 205
1.55A21.78

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		6m1d ACE2
(Homo
sapiens)		4 / 8
TYR B 649
ASP B 713
PHE D 715
LEU D 642
1.17A16.81
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
ASN C 203
ASP C 289
VAL C 296
LEU C 205
1.53A21.61

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_E_RKEE401_1
(PROTON-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
VAL C 296
LEU C 205
ASN C 203
ASP C 289
1.53A21.61

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
ASN A 203
ASP A 289
VAL A 296
LEU A 205
1.54A21.61

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
ASN C 203
ASP C 289
VAL C 296
LEU C 205
1.54A21.61

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
ASN B 203
ASP B 289
VAL B 296
LEU B 205
1.56A21.61

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
ASN B 203
ASP B 289
VAL B 296
LEU B 205
1.55A21.61

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
TYR B 209
ASP B 263
VAL B 247
LEU B 205
1.73A21.61

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
ASN D 203
ASP D 289
VAL D 296
LEU D 205
1.52A21.61

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
ASN B 203
ASP B 289
VAL B 296
LEU B 205
1.55A21.61

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
TYR B 209
ASP B 263
VAL B 247
LEU B 205
1.72A21.61

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
ASN D 203
ASP D 289
VAL D 296
LEU D 205
1.50A21.61

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
ASN A 203
ASP A 289
VAL A 296
LEU A 205
1.55A21.61

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_E_RKEE401_1
(PROTON-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
VAL A 296
LEU A 205
ASN A 203
ASP A 289
1.54A21.61

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
ASN A 203
ASP A 289
VAL A 296
LEU A 205
1.54A21.61

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
ASN D 203
ASP D 289
VAL D 296
LEU D 205
1.50A21.61

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
ASN C 203
ASP C 289
VAL C 296
LEU C 205
1.53A21.61

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
ASN B 203
ASP B 289
VAL B 296
LEU B 205
1.55A21.61

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_E_RKEE401_1
(PROTON-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
VAL B 296
LEU B 205
ASN B 203
ASP B 289
1.55A21.61

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
ASN A 203
ASP A 289
VAL A 296
LEU A 205
1.54A21.61

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
TYR B 209
ASP B 263
VAL B 247
LEU B 205
1.72A21.61

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_E_RKEE401_1
(PROTON-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
VAL D 296
LEU D 205
ASN D 203
ASP D 289
1.50A21.61

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
ASN C 203
ASP C 289
VAL C 296
LEU C 205
1.53A21.61

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		6m2n 3CL PROTEASE
(SARS-CoV-2)		4 / 8
ASN D 203
ASP D 289
VAL D 296
LEU D 205
1.51A21.61

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_E_RKEE401_1
(PROTON-GATED ION
CHANNEL)		6m2q 3CL PROTEASE
(SARS-CoV-2)		4 / 8
VAL A 296
LEU A 205
ASN A 203
ASP A 289
1.54A21.61

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		6m2q 3CL PROTEASE
(SARS-CoV-2)		4 / 8
ASN A 203
ASP A 289
VAL A 296
LEU A 205
1.54A21.61

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		6m2q 3CL PROTEASE
(SARS-CoV-2)		4 / 8
ASN A 203
ASP A 289
VAL A 296
LEU A 205
1.54A21.61

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		6m2q 3CL PROTEASE
(SARS-CoV-2)		4 / 8
ASN A 203
ASP A 289
VAL A 296
LEU A 205
1.54A21.61

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		6m2q 3CL PROTEASE
(SARS-CoV-2)		4 / 8
ASN A 203
ASP A 289
VAL A 296
LEU A 205
1.55A21.61

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		4 / 8
ASP A 465
VAL A 700
PHE A 471
LEU A 727
1.38A16.05

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		4 / 8
ASN A 209
ASP A 208
ASP A 218
LEU A 205
1.57A16.05

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_E_RKEE401_1
(PROTON-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		4 / 8
LEU A 205
ASN A 209
ASP A 208
ASP A 218
1.56A16.05

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		4 / 8
ASN A 414
ASP A 846
VAL A 848
PHE A 441
1.69A16.05

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		4 / 8
ASN A 209
ASP A 208
ASP A 218
LEU A 205
1.55A16.05

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		4 / 8
ASN A 534
ASP A 358
VAL A 373
LYS A 369
1.62A16.05

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		4 / 8
ASN A 414
ASP A 846
VAL A 848
PHE A 441
1.66A16.05

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		4 / 8
ASP A 465
VAL A 700
PHE A 471
LEU A 727
1.38A16.05

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		4 / 8
ASP A 465
VAL A 700
PHE A 471
LEU A 727
1.36A16.05

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_E_RKEE401_1
(PROTON-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		4 / 8
PHE A 157
LEU A 146
TYR A 175
ASP A 170
1.56A16.05

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		6m71 NSP7
NSP8
(SARS-CoV-2)		4 / 8
ASN D 100
ASP D  99
VAL C   6
LEU D  95
1.66A22.12

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		4 / 8
ASN A 534
ASP A 358
VAL A 373
LYS A 369
1.62A16.05

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		4 / 8
ASN A 168
ASP A 161
VAL A 174
PHE A 165
1.51A16.05

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		4 / 8
ASN A 209
ASP A 208
ASP A 218
LEU A 205
1.56A16.05

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		4 / 8
ASN A 209
ASP A 208
ASP A 218
LEU A 205
1.55A16.05

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		4 / 8
ASP A 465
VAL A 700
PHE A 471
LEU A 727
1.41A16.05

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		4 / 8
ASN A 414
ASP A 846
VAL A 848
PHE A 441
1.69A16.05

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		4 / 8
TYR A 175
ASP A 170
PHE A 157
LEU A 146
1.55A16.05

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		4 / 8
TYR A 175
ASP A 170
PHE A 157
LEU A 146
1.53A16.05

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_E_RKEE401_1
(PROTON-GATED ION
CHANNEL)		6m71 NSP12
NSP8
(SARS-CoV-2)		4 / 8
VAL A 338
PHE B  92
LEU B  91
ASP A 336
1.64A16.05

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_E_RKEE401_1
(PROTON-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		4 / 8
VAL A 848
PHE A 441
ASN A 414
ASP A 846
1.67A16.05

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		4 / 8
ASN A 168
ASP A 161
VAL A 174
PHE A 165
1.52A16.05

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_E_RKEE401_1
(PROTON-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		4 / 8
VAL A 700
PHE A 471
LEU A 727
ASP A 465
1.41A16.05

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		4 / 8
TYR A 175
ASP A 170
PHE A 157
LEU A 146
1.54A16.05

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		4 / 8
TYR A 175
ASP A 170
PHE A 157
LEU A 146
1.54A16.05

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		4 / 8
ASN A 534
ASP A 358
VAL A 373
LYS A 369
1.64A16.05

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		4 / 8
ASN A 534
ASP A 358
VAL A 373
LYS A 369
1.58A16.05

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_E_RKEE401_1
(PROTON-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		4 / 8
VAL A 373
LYS A 369
ASN A 534
ASP A 358
1.60A16.05

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		4 / 8
ASN A 414
ASP A 846
VAL A 848
PHE A 441
1.68A16.05

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		6m71 NSP12
(SARS-CoV-2)		4 / 8
ASN A 168
ASP A 161
VAL A 174
PHE A 165
1.49A16.05

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		6nus NSP12
(SARSr-CoV)		4 / 8
TYR A 175
ASP A 164
PHE A 134
LEU A 142
1.31A15.03
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		6vw1 SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
ASP E 405
ASP E 406
VAL E 350
PHE E 497
1.25A19.17
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		6w01 URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
ASP B 301
VAL B 237
PHE B 222
LEU B 228
1.32A20.05
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		6w41 CR3022 FAB LIGHT
CHAIN
(Homo
sapiens)		4 / 8
TYR L 186
ASP L 122
VAL L 133
PHE L 209
1.72A20.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_E_RKEE401_1
(PROTON-GATED ION
CHANNEL)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
VAL A 296
LEU A 205
ASN A 203
ASP A 289
1.56A21.61

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
ASN A 203
ASP A 289
VAL A 296
LEU A 205
1.56A21.61

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
ASN A 203
ASP A 289
VAL A 296
LEU A 205
1.57A21.61

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
ASN A 203
ASP A 289
VAL A 296
LEU A 205
1.56A21.61

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		6w63 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
ASN A 203
ASP A 289
VAL A 296
LEU A 205
1.56A21.61

None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		6w6y NSP3
(SARS-CoV-2)		4 / 8
TYR A 161
ASP B 162
VAL B 165
LEU A  10
1.74A20.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		6w6y NSP3
(SARS-CoV-2)		4 / 8
TYR B  17
ASN B  15
ASP B  14
VAL B 144
1.80A20.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_E_RKEE401_1
(PROTON-GATED ION
CHANNEL)		6w6y NSP3
(SARS-CoV-2)		4 / 8
VAL B 165
LEU A  10
TYR A 161
ASP B 162
1.75A20.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		6w6y NSP3
(SARS-CoV-2)		4 / 8
TYR A 161
ASP B 162
VAL B 165
LEU A  10
1.77A20.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		6w6y NSP3
(SARS-CoV-2)		4 / 8
TYR A 161
ASP B 162
VAL B 165
LEU A  10
1.75A20.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		6w6y NSP3
(SARS-CoV-2)		4 / 8
TYR A 161
ASP B 162
VAL B 165
LEU A  10
1.76A20.00
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		6w75 NSP10
(SARS-CoV-2)		4 / 8
ASP D4335
VAL B4274
PHE D4272
LEU B4328
1.70A17.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		6w75 NSP10
(SARS-CoV-2)		4 / 8
ASP D4335
VAL B4274
PHE D4272
LEU B4328
1.70A17.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		6w75 NSP10
(SARS-CoV-2)		4 / 8
ASP D4335
VAL B4274
PHE D4272
LEU B4328
1.70A17.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_E_RKEE401_1
(PROTON-GATED ION
CHANNEL)		6w75 NSP10
(SARS-CoV-2)		4 / 8
VAL B4274
PHE D4272
LEU B4328
ASP D4335
1.72A17.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		6w75 NSP10
(SARS-CoV-2)		4 / 8
ASP D4335
VAL B4274
PHE D4272
LEU B4328
1.68A17.65
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		6wey NSP3
(SARS-CoV-2)		4 / 8
TYR A 221
ASN A 219
ASP A 218
VAL A 348
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		6wiq NSP7
NSP8
(SARS-CoV-2)		4 / 8
ASN B 100
ASP B  99
VAL A   6
LEU B  95
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		6wiq NSP7
NSP8
(SARS-CoV-2)		4 / 8
ASN B 100
ASP B  99
VAL A   6
LEU B  95
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		6wiq NSP7
NSP8
(SARS-CoV-2)		4 / 8
ASN B 100
ASP B  99
VAL A   6
LEU B  95
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_E_RKEE401_1
(PROTON-GATED ION
CHANNEL)		6wiq NSP7
NSP8
(SARS-CoV-2)		4 / 8
VAL A   6
LEU B  95
ASN B 100
ASP B  99
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		6wiq NSP7
NSP8
(SARS-CoV-2)		4 / 8
ASN B 100
ASP B  99
VAL A   6
LEU B  95
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		6wjt 2'-O-METHYLTRANSFERA
SE
NSP10
(SARS-CoV-2)		4 / 8
TYR D4329
ASP D4344
VAL C6902
LEU D4328
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		6wkq NSP10
(SARS-CoV-2)		4 / 8
ASP D4335
VAL B4274
PHE D4272
LEU B4328
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		6wkq NSP10
(SARS-CoV-2)		4 / 8
ASP D4335
VAL B4274
PHE D4272
LEU B4328
1.73A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		6wkq NSP10
(SARS-CoV-2)		4 / 8
ASP D4335
VAL B4274
PHE D4272
LEU B4328
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_E_RKEE401_1
(PROTON-GATED ION
CHANNEL)		6wkq NSP10
(SARS-CoV-2)		4 / 8
VAL B4274
PHE D4272
LEU B4328
ASP D4335
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		6wkq NSP10
(SARS-CoV-2)		4 / 8
ASP D4335
VAL B4274
PHE D4272
LEU B4328
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
ASP A 133
PHE A 135
LEU A 152
LYS A 182
1.73A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
ASP B 133
PHE B 135
LEU B 143
LYS B 182
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
ASP A 133
PHE A 135
LEU A 152
LYS A 182
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
ASP A 301
VAL A 237
PHE A 222
LEU A 228
1.31A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
ASP A 133
PHE A 135
LEU A 152
LYS A 182
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_E_RKEE401_1
(PROTON-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
PHE A 135
LEU A 143
LYS A 182
ASP A 133
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
ASP B 133
PHE B 135
LEU B 143
LYS B 182
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
ASN A   5
VAL A  23
PHE A  56
LEU A   3
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_E_RKEE401_1
(PROTON-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
VAL A 237
PHE A 222
LEU A 228
ASP A 301
1.31A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
ASP B 133
PHE B 135
LEU B 152
LYS B 182
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
ASP B 133
PHE B 135
LEU B 152
LYS B 182
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
ASP B 133
PHE B 135
LEU B 143
LYS B 182
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
ASP B 301
VAL B 237
PHE B 222
LEU B 228
1.31A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
ASP B 301
VAL B 237
PHE B 222
LEU B 228
1.31A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_E_RKEE401_1
(PROTON-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
PHE A 135
LEU A 152
LYS A 182
ASP A 133
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
ASP B 301
VAL B 237
PHE B 222
LEU B 228
1.30A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
ASP B 301
VAL B 237
PHE B 222
LEU B 228
1.31A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
ASP A 301
VAL A 237
PHE A 222
LEU A 228
1.32A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
ASP B 133
PHE B 135
LEU B 152
LYS B 182
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
ASP A 301
VAL A 237
PHE A 222
LEU A 228
1.32A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
ASP A 133
PHE A 135
LEU A 143
LYS A 182
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_E_RKEE401_1
(PROTON-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
PHE B 135
LEU B 152
LYS B 182
ASP B 133
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
ASP A 133
PHE A 135
LEU A 152
LYS A 182
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
ASP B 133
PHE B 135
LEU B 143
LYS B 182
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
ASP A 133
PHE A 135
LEU A 143
LYS A 182
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_E_RKEE401_1
(PROTON-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
VAL B 237
PHE B 222
LEU B 228
ASP B 301
1.30A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
ASP B 133
PHE B 135
LEU B 152
LYS B 182
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_E_RKEE401_1
(PROTON-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
PHE B 135
LEU B 143
LYS B 182
ASP B 133
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
ASP A 301
VAL A 237
PHE A 222
LEU A 228
1.32A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
ASP A 133
PHE A 135
LEU A 143
LYS A 182
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		6wlc URIDYLATE-SPECIFIC
ENDORIBONUCLEASE
(SARS-CoV-2)		4 / 8
ASP A 133
PHE A 135
LEU A 143
LYS A 182
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
ASN A 203
ASP A 289
VAL A 296
LEU A 205
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
ASN A 203
ASP A 289
VAL A 296
LEU A 205
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
ASN A 203
ASP A 289
VAL A 296
LEU A 205
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_E_RKEE401_1
(PROTON-GATED ION
CHANNEL)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
VAL A 296
LEU A 205
ASN A 203
ASP A 289
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		6wnp 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
ASN A 203
ASP A 289
VAL A 296
LEU A 205
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
TYR D  17
ASN D  15
ASP D  14
VAL D 144
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		6woj REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
TYR A  17
ASN A  15
ASP A  14
VAL A 144
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
TYR A 209
ASP A 263
VAL A 247
LEU A 205
1.73A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
TYR A 209
ASP A 263
VAL A 247
LEU A 205
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
ASN A 203
ASP A 289
VAL A 296
LEU A 205
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_E_RKEE401_1
(PROTON-GATED ION
CHANNEL)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
VAL A 296
LEU A 205
ASN A 203
ASP A 289
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
TYR A 209
ASP A 263
VAL A 247
LEU A 205
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
ASN A 203
ASP A 289
VAL A 296
LEU A 205
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
ASN A 203
ASP A 289
VAL A 296
LEU A 205
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
TYR A 209
ASP A 263
VAL A 247
LEU A 205
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_E_RKEE401_1
(PROTON-GATED ION
CHANNEL)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
VAL A 247
LEU A 205
TYR A 209
ASP A 263
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_E_RKEE401_1
(PROTON-GATED ION
CHANNEL)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
VAL A 171
LYS A 137
ASN A 133
ASP A 197
1.80A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		6wqf 3C-LIKE PROTEINASE
(SARS-CoV-2)		4 / 8
ASN A 203
ASP A 289
VAL A 296
LEU A 205
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
ASN A 203
ASP A 289
VAL A 296
LEU A 205
1.51A18.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_E_RKEE401_1
(PROTON-GATED ION
CHANNEL)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
VAL A 296
LEU A 205
ASN A 203
ASP A 289
1.51A18.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
ASN A 203
ASP A 289
VAL A 296
LEU A 205
1.51A18.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
ASN A 203
ASP A 289
VAL A 296
LEU A 205
1.52A18.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		6yb7 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
ASN A 203
ASP A 289
VAL A 296
LEU A 205
1.53A18.50
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		4 / 8
ASN B 100
ASP B 101
VAL A   6
LYS A   2
1.62A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		4 / 8
ASN B 100
ASP B 101
VAL A   6
LYS A   2
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		4 / 8
ASN B 100
ASP B 101
VAL A   6
LYS A   2
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		4 / 8
ASN B 100
ASP B 101
VAL A   6
LYS A   2
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_E_RKEE401_1
(PROTON-GATED ION
CHANNEL)		6yhu REPLICASE
POLYPROTEIN 1A
(SARS-CoV-2)		4 / 8
VAL A   6
LYS A   2
ASN B 100
ASP B 101
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_E_RKEE401_1
(PROTON-GATED ION
CHANNEL)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		4 / 8
VAL L  64
LYS B   0
TYR L  42
ASP H 107
1.76A
None
MLI  B 303 (-4.6A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_E_RKEE401_1
(PROTON-GATED ION
CHANNEL)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
VAL A 382
PHE A 392
LEU A 517
ASP A 389
1.65A
DMS  A 905 (-4.3A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		6yla LIGHT CHAIN
(Homo
sapiens)		4 / 8
TYR L 192
ASP L 128
VAL L 139
PHE L 215
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
ASP A 389
VAL A 382
PHE A 392
LEU A 517
1.63A
None
DMS  A 905 (-4.3A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		4 / 8
TYR L  42
ASP H 107
VAL L  64
LYS B   0
1.78A
None
None
None
MLI  B 303 (-4.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		6yla LIGHT CHAIN
(Homo
sapiens)		4 / 8
TYR L 192
ASP L 128
VAL L 139
PHE L 215
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		4 / 8
TYR C  42
ASP B 107
VAL C  64
LYS H   0
1.76A
None
None
None
MLI  B 303 (-4.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		4 / 8
TYR C  42
ASP B 107
VAL C  64
LYS H   0
1.75A
None
None
None
MLI  B 303 (-4.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
TYR E 365
VAL E 341
LEU E 513
LYS E 356
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		6yla LIGHT CHAIN
(Homo
sapiens)		4 / 8
TYR L 192
ASP L 128
VAL L 139
PHE L 215
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
ASP A 389
VAL A 382
PHE A 392
LEU A 517
1.63A
None
DMS  A 905 (-4.3A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		4 / 8
TYR L  42
ASP H 107
VAL L  64
LYS B   0
1.76A
None
None
None
MLI  B 303 (-4.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		4 / 8
TYR L  42
ASP H 107
VAL L  64
LYS B   0
1.74A
None
None
None
MLI  B 303 (-4.6A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		4 / 8
TYR C  42
ASP B 107
VAL C  64
LYS H   0
1.73A
None
None
None
MLI  B 303 (-4.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
ASP A 389
VAL A 382
PHE A 392
LEU A 517
1.66A
None
DMS  A 905 (-4.3A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		4 / 8
TYR C  42
ASP B 107
VAL C  64
LYS H   0
1.77A
None
None
None
MLI  B 303 (-4.3A)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		6yla LIGHT CHAIN
(Homo
sapiens)		4 / 8
TYR C 192
ASP C 128
VAL C 139
PHE C 215
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_E_RKEE401_1
(PROTON-GATED ION
CHANNEL)		6yla HEAVY CHAIN
LIGHT CHAIN
(Homo
sapiens)		4 / 8
VAL C  64
LYS H   0
TYR C  42
ASP B 107
1.74A
None
MLI  B 303 (-4.3A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
ASP A 389
VAL A 382
PHE A 392
LEU A 517
1.64A
None
DMS  A 905 (-4.3A)
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		6yla SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
TYR A 365
VAL A 341
LEU A 513
LYS A 356
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		6ym0 LIGHT CHAIN
(Homo
sapiens)		4 / 8
TYR L 192
ASP L 128
VAL L 139
PHE L 215
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
ASP A 245
ASP A 248
VAL A 261
LEU A 242
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
ASN A 203
ASP A 289
VAL A 296
LEU A 205
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
ASN A 203
ASP A 289
VAL A 296
LEU A 205
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
ASN A 203
ASP A 289
VAL A 296
LEU A 205
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
ASP A 245
ASP A 248
VAL A 261
LEU A 242
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
ASN A 203
ASP A 289
VAL A 296
LEU A 205
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
ASP A 245
ASP A 248
VAL A 261
LEU A 242
1.80A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_E_RKEE401_1
(PROTON-GATED ION
CHANNEL)		6ynq REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
VAL A 296
LEU A 205
ASN A 203
ASP A 289
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		6yor IGG L CHAIN
(Homo
sapiens)		4 / 8
TYR C 192
ASP C 128
VAL C 139
PHE C 215
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
TYR A 365
VAL A 341
LEU A 513
LYS A 356
1.80A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		6yor SPIKE GLYCOPROTEIN
(SARS-CoV-2)		4 / 8
TYR E 365
VAL E 341
LEU E 513
LYS E 356
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		6yor IGG L CHAIN
(Homo
sapiens)		4 / 8
TYR L 192
ASP L 128
VAL L 139
PHE L 215
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		6yor IGG L CHAIN
(Homo
sapiens)		4 / 8
TYR C 192
ASP C 128
VAL C 139
PHE C 215
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		6yor IGG L CHAIN
(Homo
sapiens)		4 / 8
TYR L 192
ASP L 128
VAL L 139
PHE L 215
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		6yor IGG L CHAIN
(Homo
sapiens)		4 / 8
TYR L 192
ASP L 128
VAL L 139
PHE L 215
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_E_RKEE401_1
(PROTON-GATED ION
CHANNEL)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
VAL A 261
LEU A 242
ASP A 245
ASP A 248
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
ASP A 245
ASP A 248
VAL A 261
LEU A 242
1.80A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
ASP A 245
ASP A 248
VAL A 261
LEU A 242
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
ASN A 203
ASP A 289
VAL A 296
LEU A 205
1.56A
PEG  A 405 ( 4.9A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_E_RKEE401_1
(PROTON-GATED ION
CHANNEL)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
VAL A 296
LEU A 205
ASN A 203
ASP A 289
1.54A
None
None
PEG  A 405 ( 4.9A)
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
ASP A 245
ASP A 248
VAL A 261
LEU A 242
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
ASN A 203
ASP A 289
VAL A 296
LEU A 205
1.55A
PEG  A 405 ( 4.9A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
ASP A 245
ASP A 248
VAL A 261
LEU A 242
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
ASN A 203
ASP A 289
VAL A 296
LEU A 205
1.55A
PEG  A 405 ( 4.9A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		6yt8 REPLICASE
POLYPROTEIN 1AB
(SARS-CoV-2)		4 / 8
ASN A 203
ASP A 289
VAL A 296
LEU A 205
1.54A
PEG  A 405 ( 4.9A)
None
None
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		7bqy MAIN PROTEASE
(SARS-CoV-2)		4 / 8
ASN A 203
ASP A 289
VAL A 296
LEU A 205
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		7bqy MAIN PROTEASE
(SARS-CoV-2)		4 / 8
ASP A 229
VAL A 233
LEU A 242
LYS A 269
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		7bqy MAIN PROTEASE
(SARS-CoV-2)		4 / 8
ASP A 229
VAL A 233
LEU A 242
LYS A 269
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		7bqy MAIN PROTEASE
(SARS-CoV-2)		4 / 8
ASP A 229
VAL A 233
LEU A 242
LYS A 269
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_E_RKEE401_1
(PROTON-GATED ION
CHANNEL)		7bqy MAIN PROTEASE
(SARS-CoV-2)		4 / 8
VAL A 233
LEU A 242
LYS A 269
ASP A 229
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		7bqy MAIN PROTEASE
(SARS-CoV-2)		4 / 8
ASN A 203
ASP A 289
VAL A 296
LEU A 205
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		7bqy MAIN PROTEASE
(SARS-CoV-2)		4 / 8
ASN A 203
ASP A 289
VAL A 296
LEU A 205
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		7bqy MAIN PROTEASE
(SARS-CoV-2)		4 / 8
ASP A 229
VAL A 233
LEU A 242
LYS A 269
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_E_RKEE401_1
(PROTON-GATED ION
CHANNEL)		7bqy MAIN PROTEASE
(SARS-CoV-2)		4 / 8
VAL A 296
LEU A 205
ASN A 203
ASP A 289
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		7bqy MAIN PROTEASE
(SARS-CoV-2)		4 / 8
ASN A 203
ASP A 289
VAL A 296
LEU A 205
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 8
TYR A 175
ASP A 170
PHE A 157
LEU A 146
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 8
ASN A 209
ASP A 208
ASP A 218
LEU A 205
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		7btf NSP12
NSP7
(SARS-CoV-2)		4 / 8
TYR A 420
ASP C   5
VAL C  11
LEU A 437
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 8
TYR A 619
ASN A 695
VAL A 764
PHE A 782
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 8
TYR A 237
ASP A  36
ASP A 208
LEU A 205
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		7btf NSP12
NSP7
(SARS-CoV-2)		4 / 8
TYR A 420
ASP C   5
VAL C  11
LEU A 437
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 8
ASN A 209
ASP A 218
PHE A 222
LEU A 205
1.73A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 8
ASN A 534
ASP A 358
VAL A 373
LYS A 369
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 8
ASP A 218
ASP A 221
PHE A 192
LEU A  90
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 8
ASN A 209
ASP A 208
ASP A 218
LEU A 205
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 8
ASN A 534
ASP A 358
VAL A 373
LYS A 369
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 8
TYR A 619
ASN A 695
VAL A 764
PHE A 782
1.78A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 8
TYR A 237
ASP A  36
ASP A 208
LEU A 205
1.67A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_E_RKEE401_1
(PROTON-GATED ION
CHANNEL)		7btf NSP12
NSP7
(SARS-CoV-2)		4 / 8
VAL C  11
LEU A 437
TYR A 420
ASP C   5
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 8
ASP A 218
ASP A 221
PHE A 192
LEU A  90
1.65A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 8
ASN A 534
ASP A 358
VAL A 373
LYS A 369
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 8
ASN A 209
ASP A 208
ASP A 218
LEU A 205
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_E_RKEE401_1
(PROTON-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 8
VAL A 764
PHE A 782
TYR A 619
ASN A 695
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 8
ASP A 465
VAL A 700
PHE A 471
LEU A 727
1.41A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_E_RKEE401_1
(PROTON-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 8
VAL A 700
PHE A 471
LEU A 727
ASP A 465
1.44A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_E_RKEE401_1
(PROTON-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 8
LEU A 205
ASN A 209
ASP A 208
ASP A 218
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_E_RKEE401_1
(PROTON-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 8
VAL A 373
LYS A 369
ASN A 534
ASP A 358
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_E_RKEE401_1
(PROTON-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 8
PHE A 192
LEU A  90
ASP A 218
ASP A 221
1.66A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 8
ASN A 209
ASP A 208
ASP A 218
LEU A 205
1.58A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		7btf NSP12
NSP7
(SARS-CoV-2)		4 / 8
TYR A 420
ASP C   5
VAL C  11
LEU A 437
1.60A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 8
TYR A 175
ASP A 170
PHE A 157
LEU A 146
1.68A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 8
ASN A 534
ASP A 358
VAL A 373
LYS A 369
1.61A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 8
ASP A 218
ASP A 221
PHE A 192
LEU A  90
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 8
ASP A 465
VAL A 700
PHE A 471
LEU A 727
1.42A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 8
ASP A 164
VAL A 792
LEU A 460
LYS A 621
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 8
ASP A 218
VAL A  96
PHE A 222
LEU A 205
1.57A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		7btf NSP12
NSP7
(SARS-CoV-2)		4 / 8
TYR A 420
ASP C   5
VAL C  11
LEU A 437
1.59A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 8
ASP A 218
ASP A 221
PHE A 192
LEU A  90
1.64A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		7btf NSP12
(SARS-CoV-2)		4 / 8
ASP A 465
VAL A 700
PHE A 471
LEU A 727
1.39A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		4 / 8
ASN A 203
ASP A 289
VAL A 296
LEU A 205
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		4 / 8
ASN A 203
ASP A 289
VAL A 296
LEU A 205
1.56A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_E_RKEE401_1
(PROTON-GATED ION
CHANNEL)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		4 / 8
VAL A 296
LEU A 205
ASN A 203
ASP A 289
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		4 / 8
ASN A 203
ASP A 289
VAL A 296
LEU A 205
1.55A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		7buy VIRUS MAIN PROTEASE
(SARS-CoV-2)		4 / 8
ASN A 203
ASP A 289
VAL A 296
LEU A 205
1.54A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_E_RKEE401_1
(PROTON-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
VAL A 700
PHE A 471
LEU A 727
ASP A 465
1.41A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
ASN A 534
ASP A 358
VAL A 373
LYS A 369
1.72A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
TYR A 175
ASP A 170
PHE A 157
LEU A 146
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
ASP A 465
VAL A 700
PHE A 471
LEU A 727
1.38A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
TYR A 175
ASP A 170
PHE A 157
LEU A 146
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
ASN A 909
ASP A 910
PHE A 881
LEU A 885
1.79A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
ASN A 534
ASP A 358
VAL A 373
LYS A 369
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
ASN A 909
ASP A 910
PHE A 881
LEU A 885
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_E_RKEE401_1
(PROTON-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
PHE A 881
LEU A 885
ASN A 909
ASP A 910
1.77A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
ASN A 909
ASP A 910
PHE A 881
LEU A 885
1.76A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
ASP A 465
VAL A 700
PHE A 471
LEU A 727
1.38A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_E_RKEE401_1
(PROTON-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
VAL A 373
LYS A 369
ASN A 534
ASP A 358
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
TYR A 175
ASP A 170
PHE A 157
LEU A 146
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
ASN A 909
ASP A 910
PHE A 881
LEU A 885
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
ASP A 465
VAL A 700
PHE A 471
LEU A 727
1.36A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
TYR A 175
ASP A 170
PHE A 157
LEU A 146
1.70A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
ASN A 534
ASP A 358
VAL A 373
LYS A 369
1.69A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		7bv1 NSP12
(SARS-CoV-2)		4 / 8
ASN A 534
ASP A 358
VAL A 373
LYS A 369
1.71A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
ASP A 465
VAL A 700
PHE A 471
LEU A 727
1.35A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
ASP A 465
VAL A 700
PHE A 471
LEU A 727
1.40A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
ASP A 465
VAL A 700
PHE A 471
LEU A 727
1.36A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_E_RKEE401_1
(PROTON-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
VAL A 700
PHE A 471
LEU A 727
ASP A 465
1.39A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_D_RKED401_1
(PROTON-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
TYR A 175
ASP A 164
PHE A 134
LEU A 142
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
ASN A 534
ASP A 358
VAL A 373
LYS A 369
1.75A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_B_RKEB401_1
(PROTON-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
TYR A 175
ASP A 164
PHE A 134
LEU A 142
1.51A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_E_RKEE401_1
(PROTON-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
PHE A 134
LEU A 142
TYR A 175
ASP A 164
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
TYR A 175
ASP A 164
PHE A 134
LEU A 142
1.50A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
ASN A 534
ASP A 358
VAL A 373
LYS A 369
1.74A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_A_RKEA401_1
(PROTON-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
TYR A 175
ASP A 164
PHE A 134
LEU A 142
1.52A
None
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.
4F8H_C_RKEC401_1
(PROTON-GATED ION
CHANNEL)		7bv2 NSP12
(SARS-CoV-2)		4 / 8
ASP A 465
VAL A 700
PHE A 471
LEU A 727
1.37A
None